Brain Dynamics Centre, Westmead Millennium Institute and Psychiatry, University of Sydney Medical School-Westmead, Westmead Hospital, Westmead, Sydney, NSW, Australia.
Expert Rev Neurother. 2012 Jul;12(7):835-47. doi: 10.1586/ern.12.72.
Melancholia is typified by features of psychomotor slowing, anxiety, appetite loss and sleep changes. It is usually observed in 20-30% of individuals meeting diagnostic criteria for major depressive disorder (MDD). There is currently no agreement on whether melancholic MDD represents a distinct entity defined by neurobiological as well as clinical features or, rather, a specifier for MDD. This situation is reflected in the revisions to DSM, including in the DSM-5 due for release in 2013. With this context in mind, the authors review the origins of the construct of melancholia in MDD, its theoretical grounding and the defining characteristics that arose from this research. The authors then outline the state of knowledge on the neurobiology of melancholia. This second aspect is illustrative of the National Institutes of Mental Health's research domain criteria initiative, which offers a framework for redefining constructs along neurobiological dimensions. The authors also consider the outlook for identifying a useful biosignature of melancholia.
忧郁症的特征包括精神运动迟缓、焦虑、食欲减退和睡眠改变。它通常在符合重度抑郁症(MDD)诊断标准的个体中观察到 20-30%。目前尚无共识认为忧郁性 MDD 是否代表一种由神经生物学和临床特征定义的独特实体,或者更确切地说,是否代表 MDD 的一个特定表现。这种情况反映在 DSM 的修订中,包括即将在 2013 年发布的 DSM-5。有鉴于此,作者回顾了 MDD 中忧郁症的概念的起源、其理论基础以及由此产生的定义特征。作者随后概述了忧郁症神经生物学的知识现状。这第二个方面说明了美国国立精神卫生研究所的研究领域标准倡议,该倡议提供了一个沿着神经生物学维度重新定义概念的框架。作者还考虑了确定忧郁症有用的生物标志物的前景。